Elisabeth Björk

Board Member

Elisabeth Björk (born 1961) is Board member since 2025.

She has more than 30 years of experience from clinical practice, academic research and drug development, including leading positions in various roles at AstraZeneca for more than 20 years. She has worked strategically and operationally covering the clinical development phases I-IV, large-scale outcomes programs, major global filings and health authority interactions, as well as commercial strategy and implementation.

Elisabeth is an endocrinologist by training and an associate professor of medicine at Uppsala University, Sweden. She holds an MD from the Karolinska Institute and a Ph.D. in Endocrinology from Uppsala University.

Other current appointments: Board member of Vicore Pharma AB, Pharvaris N.V., Rocket Pharmaceuticals, Inc., Agiana Pharma AS and Betula Consulting AB.

Holdings in the company: 250 shares

Independent in relation to the company and its management and the company’s major shareholders.